Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy
Metabolically Healthy Obesity (MHO) is generally recognized as the absence of any metabolic disorders and cardiovascular diseases, including type 2 diabetes, dyslipidemia, and hypertension, in obese individuals; however, it is not clearly defined. Therefore, the present study investigated difference...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2023-12-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0189/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591727620259840 |
|---|---|
| author | Shiori Kawai Hajime Yamakage Kazuhiko Kotani Mitsuhiko Noda Noriko Satoh-Asahara Koshi Hashimoto |
| author_facet | Shiori Kawai Hajime Yamakage Kazuhiko Kotani Mitsuhiko Noda Noriko Satoh-Asahara Koshi Hashimoto |
| author_sort | Shiori Kawai |
| collection | DOAJ |
| description | Metabolically Healthy Obesity (MHO) is generally recognized as the absence of any metabolic disorders and cardiovascular diseases, including type 2 diabetes, dyslipidemia, and hypertension, in obese individuals; however, it is not clearly defined. Therefore, the present study investigated differences in metabolic characteristics between individuals with MHO and Metabolically Unhealthy Obesity (MUO) during weight reduction therapy. The key factors defining MHO and the importance of weight reduction therapy for MHO were also examined. Cohort data from the Japan Obesity and Metabolic Syndrome (JOMS) study were analyzed. Subjects were divided into the MHO (n = 25) and MUO (n = 120) groups. Prior to weight reduction therapy, serum adiponectin levels were significantly higher in the MHO group than in the MUO group. Serum adiponectin levels also negatively correlated with the area of subcutaneous adipose tissue (SAT) and Homeostasis model assessment (HOMA)-R in the MHO group, but not in the MUO group. Collectively, the present results suggest the importance of adiponectin for maintaining metabolic homeostasis in the MHO group. On the other hand, no significant differences were observed in inflammatory markers between the MHO and MUO groups, suggesting the presence of chronic inflammation in both groups. Furthermore, a positive correlation was noted between changes in serum cystatin C levels and waist circumference in the MHO group, which indicated that despite the absence of metabolic disorders, the MHO group exhibited anti-inflammatory responses during weight reduction therapy. These results underscore the significance of weight reduction even for individuals with MHO. |
| format | Article |
| id | doaj-art-bcf5f6d6ecfe493ab0dad968242882ea |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-bcf5f6d6ecfe493ab0dad968242882ea2025-01-22T06:25:09ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402023-12-0170121175118610.1507/endocrj.EJ23-0189endocrjDifferences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapyShiori Kawai0Hajime Yamakage1Kazuhiko Kotani2Mitsuhiko Noda3Noriko Satoh-Asahara4Koshi Hashimoto5Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, JapanDivision of Diabetic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, JapanDivision of Community and Family Medicine, Jichi Medical University, Tochigi 329-0498, JapanDepartment of Diabetes, Metabolism and Endocrinology, Ichikawa Hospital, International University of Health and Welfare, Chiba 272-0827, JapanDivision of Diabetic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, JapanDepartment of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, JapanMetabolically Healthy Obesity (MHO) is generally recognized as the absence of any metabolic disorders and cardiovascular diseases, including type 2 diabetes, dyslipidemia, and hypertension, in obese individuals; however, it is not clearly defined. Therefore, the present study investigated differences in metabolic characteristics between individuals with MHO and Metabolically Unhealthy Obesity (MUO) during weight reduction therapy. The key factors defining MHO and the importance of weight reduction therapy for MHO were also examined. Cohort data from the Japan Obesity and Metabolic Syndrome (JOMS) study were analyzed. Subjects were divided into the MHO (n = 25) and MUO (n = 120) groups. Prior to weight reduction therapy, serum adiponectin levels were significantly higher in the MHO group than in the MUO group. Serum adiponectin levels also negatively correlated with the area of subcutaneous adipose tissue (SAT) and Homeostasis model assessment (HOMA)-R in the MHO group, but not in the MUO group. Collectively, the present results suggest the importance of adiponectin for maintaining metabolic homeostasis in the MHO group. On the other hand, no significant differences were observed in inflammatory markers between the MHO and MUO groups, suggesting the presence of chronic inflammation in both groups. Furthermore, a positive correlation was noted between changes in serum cystatin C levels and waist circumference in the MHO group, which indicated that despite the absence of metabolic disorders, the MHO group exhibited anti-inflammatory responses during weight reduction therapy. These results underscore the significance of weight reduction even for individuals with MHO.https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0189/_html/-char/enmetabolically healthy obesity (mho)metabolically unhealthy obesity (muo)weight reduction therapycystatin cadiponectin |
| spellingShingle | Shiori Kawai Hajime Yamakage Kazuhiko Kotani Mitsuhiko Noda Noriko Satoh-Asahara Koshi Hashimoto Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy Endocrine Journal metabolically healthy obesity (mho) metabolically unhealthy obesity (muo) weight reduction therapy cystatin c adiponectin |
| title | Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy |
| title_full | Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy |
| title_fullStr | Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy |
| title_full_unstemmed | Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy |
| title_short | Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy |
| title_sort | differences in metabolic characteristics between metabolically healthy obesity mho and metabolically unhealthy obesity muo in weight reduction therapy |
| topic | metabolically healthy obesity (mho) metabolically unhealthy obesity (muo) weight reduction therapy cystatin c adiponectin |
| url | https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0189/_html/-char/en |
| work_keys_str_mv | AT shiorikawai differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy AT hajimeyamakage differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy AT kazuhikokotani differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy AT mitsuhikonoda differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy AT norikosatohasahara differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy AT koshihashimoto differencesinmetaboliccharacteristicsbetweenmetabolicallyhealthyobesitymhoandmetabolicallyunhealthyobesitymuoinweightreductiontherapy |